CIK 0001919246 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pelthos Therapeutics Inc.
Sign in to watch- Ticker
- PTHS
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 863335449
- Phone
- 919-908-2422
- Business address
- 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
- Former names
- Channel Therapeutics Corp, Chromocell Therapeutics Corp
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Planned sale Director sold 558 shares at an average $26.09 ($14,556)
- 4 Planned sale Director sold 786 shares at an average $26.16 ($20,561)
- 4 Planned sale Director sold 797 shares at an average $26.13 ($20,827)
- 4 Planned sale Director sold 283 shares at an average $27.29 ($7,724)
- 4 Open-market buy Director bought 35,948 shares at an average $27.82 ($999,983)
- 8-K Event Regulation FD disclosure
- 4 Open-market sale CFO, Treas & Secty sold 1,500 shares at $26.84 ($40,265)
- 144 Insider Sale of Securities
- 8-K Event Auditor change · Executive or director change
- 4 Shares withheld for taxes Director gave up 144 shares (to pay taxes)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Results of operations · Regulation FD disclosure
- 10-Q Report Quarterly Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 3 Insider Initial Statement of Ownership
- 8-K Event Regulation FD disclosure
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Planned sale Director sold 590 shares at an average $20.92 ($12,340)
- 4 Planned sale Director sold 558 shares at an average $20.92 ($11,671)
Page 2 of 13 · 258 filings